947144-60-7 Usage
Appearance
Yellow crystalline solid The compound has a yellow color and a crystalline structure, which refers to its solid form with a well-defined pattern of atoms or molecules.
Uses
Intermediate in the synthesis of pharmaceuticals and agrochemicals 2,6-dibromo-3-nitro-4-chloropyridine is commonly used as a starting material or building block in the production of various medications and chemicals used in agriculture.
Antimicrobial and antifungal properties
Strong The compound is known for its ability to inhibit the growth of microorganisms and fungi, making it a valuable component in the development of medications and pesticides.
Applications
Production of dyes and pigments 2,6-dibromo-3-nitro-4-chloropyridine is also used in the manufacturing of colorants for various industries.
Potential toxicity
High Due to its toxic nature, it is essential to handle and use the compound with caution and follow proper safety protocols to minimize the risk of exposure and harm.
Check Digit Verification of cas no
The CAS Registry Mumber 947144-60-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,7,1,4 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 947144-60:
(8*9)+(7*4)+(6*7)+(5*1)+(4*4)+(3*4)+(2*6)+(1*0)=187
187 % 10 = 7
So 947144-60-7 is a valid CAS Registry Number.
947144-60-7Relevant academic research and scientific papers
A flexible synthesis of C-6 and N-1 analogues of a 4-amino-1,3- dihydroimidazo[4,5-c]pyridin-2-one core
Hay, Duncan A.,Adam, Fiona M.,Bish, Gerwyn,Calo, Frederick,Dixon, Rachel,Fray, M. Jonathan,Hitchin, James,Jones, Peter,Paradowski, Michael,Parsons, Gemma C.,Proctor, Katie J.W.,Pryde, David C.,Smith, Nicholas N.
, p. 5728 - 5732 (2011/12/03)
A flexible route which enables access to derivatives of 4-amino-1,3-dihydroimidazo[4,5-c]pyridin-2-ones is described. Issues of selectivity, reaction safety, and low yields in original routes are overcome with the key improvements to the route, including
NOVEL PHARMACEUTICALS
-
Page/Page column 51; 70, (2010/11/28)
The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.
